PROGNYX

Home/The Watchtower/SOTIO's SOT106 ADC lands FDA Orphan Drug and osteosarcoma…

Editorial illustration for the Prognyx briefing on SOT106 — antibody-drug conjugate (undisclosed target)

Briefing · From the Watchtower

SOTIO's SOT106 ADC lands FDA Orphan Drug and osteosarcoma Fast Track

The LRRC15-targeting antibody-drug conjugate now holds Orphan Drug status in soft tissue sarcoma and Fast Track in osteosarcoma, per SOTIO — but it has yet to dose a patient.

By · Founder, Prognyx ● Sourced to primary records Oncology
In brief — SOTIO Biotech said on 23 September 2026 that the FDA granted its LRRC15-targeting antibody-drug conjugate SOT106 Orphan Drug designation in soft tissue sarcoma and Fast Track designation in osteosarcoma, adding to a Fast Track it already held in soft tissue sarcoma from 26 August 2026. The designations ease the regulatory path but carry no decision clock: SOT106's Phase 1/2 trial (NCT07801222) was not yet open as of the 3 September 2026 registry record, with dosing slated to begin 30 September 2026 and primary completion set for January 2029.

SOTIO stacks FDA designations on a sarcoma ADC that has not yet dosed a patient

SOTIO Biotech said on 23 September 2026 that the FDA granted its SOT106 antibody-drug conjugate two new designations: Orphan Drug status in soft tissue sarcoma and Fast Track status in osteosarcoma [1]. The announcement builds on a Fast Track the agency had already given SOT106 in soft tissue sarcoma on 26 August 2026 [2]. SOTIO characterizes SOT106 as a potential best-in-class ADC for sarcoma — the company's own framing, not an independent finding [1].

What the designations do not change: SOT106 has not dosed a patient. Its Phase 1/2 study, NCT07801222, was registered as not yet open as of the 3 September 2026 registry record, with a listed start date of 30 September 2026 and primary completion set for 19 January 2029 [3]. The trial plans to enroll 70 patients with LRRC15-positive advanced or metastatic osteosarcoma or soft tissue sarcoma; SOT106 is designed to home in on the LRRC15 marker and kill cells carrying it while sparing healthy tissue [3].

Why it matters

For a development-stage sarcoma asset, these designations lower regulatory friction rather than move a decision. Fast Track opens more frequent FDA interaction and the option of rolling review; Orphan Drug status carries development incentives and market exclusivity that attach only on approval. Neither sets a review clock — there is no filing, no acceptance and therefore no target action date to derive. The only calendar the record supports is the trial's own: enrollment opening around 30 September 2026 and a primary completion date of 19 January 2029 [3]. A competitor cannot act on an efficacy signal here, because none exists yet; what has changed is the regulatory runway, not the evidence.

The move also reads as a pipeline signal. SOT106 sits alongside SOT109, a CDH17-targeting ADC for colorectal cancer whose first patient was dosed in the CADENCIA-01 trial on 9 September 2026 [4], and SOT201, a clinical-stage immunocytokine whose European patent protection the EPO confirmed on 21 July 2026 [5]. Inside two months SOTIO has notched a first dose, a patent confirmation and a dual designation — a company pushing three distinct oncology assets through early clinical and IP milestones in quick succession.

What to watch next

  • Trial opening and first dosing for NCT07801222, listed to start 30 September 2026 [3].
  • Whether the FDA designations shift that recruitment timeline — the not-yet-open status is dated 3 September 2026, before the designation news, and the record does not confirm any change [3].
  • Primary completion of the Phase 1/2 study, listed for 19 January 2029 [3].

The now-what

For an operator tracking LRRC15 or ADCs in bone and soft tissue sarcoma, the practical read is narrow. First, treat this as a regulatory-runway event, not a data event: there is nothing to benchmark against until the trial reads out. Second, set NCT07801222's opening as the near-term trigger and watch for a first-in-human disclosure after 30 September 2026 rather than reacting to the designation itself. Third, if SOT106's LRRC15 mechanism overlaps a program in your portfolio, the designation stack signals SOTIO intends an accelerated regulatory posture — worth monitoring for competitive positioning even though efficacy remains unproven.

What Prognyx could not verify

The designations are sourced to SOTIO's own release; no independent press report in the retrieved set confirms them [1]. The record does not clarify whether the 23 September "dual designation" reiterates or supersedes the 26 August soft tissue sarcoma Fast Track, and the full press-release text was available only in summary [1][2]. The trial's not-yet-open status predates the news, so any effect on its timeline is unconfirmed [3]. SOT106's payload and mechanism beyond LRRC15 targeting are not detailed in the record [3].

Verdict: low near-term competitive threat — no efficacy data exists — with the first real watch point the trial's planned 30 September 2026 opening.

Questions this briefing answers

What did the FDA grant SOT106 on 23 September 2026?

Per SOTIO's release, the FDA granted SOT106 Orphan Drug designation in soft tissue sarcoma and Fast Track designation in osteosarcoma. This added to a Fast Track designation the agency had already granted the drug in soft tissue sarcoma on 26 August 2026.

Has SOT106 been tested in patients yet?

Not as of the record. Its Phase 1/2 trial, NCT07801222, was registered as not yet open as of the 3 September 2026 registry snapshot, with a listed start date of 30 September 2026 and primary completion set for 19 January 2029. The 70-patient study enrolls people with LRRC15-positive advanced or metastatic osteosarcoma or soft tissue sarcoma.

Sources — every claim traces to the primary record

  1. SOTIO release, dual FDA designations for SOT106 (GlobeNewswire, 23 September 2026)
  2. SOTIO release, SOT106 Fast Track in soft tissue sarcoma (GlobeNewswire, 26 August 2026)
  3. ClinicalTrials.gov NCT07801222
  4. SOTIO release, first patient dosed in CADENCIA-01 (SOT109) (GlobeNewswire, 9 September 2026)
  5. SOTIO release, EPO confirms SOT201 patent protection (GlobeNewswire, 21 July 2026)

How this briefing was produced — Drafted and audited by the Prognyx engine against the primary sources cited above, then published automatically for clearing the audit threshold set by Rali Filali. Below that threshold, a briefing is not published. The full method.

Want this on your pipeline?
Get a free sample competitive brief on one of your assets — sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.

Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use.